Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report

Angela L Liang; Payam Katebi Kashi; Mark Hopkins; Anna Beavis; Stephanie Gaillard; Ie-Ming Shih; Amanda N Fader

doi:10.1016/j.gore.2021.100877

Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report

Gynecol Oncol Rep. 2021 Oct 4:38:100877. doi: 10.1016/j.gore.2021.100877. eCollection 2021 Nov.

Authors

Angela L Liang¹, Payam Katebi Kashi¹, Mark Hopkins², Anna Beavis¹, Stephanie Gaillard^{1

3}, Ie-Ming Shih², Amanda N Fader¹

Affiliations

¹ The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD 21287, United States.
² Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21287, United States.
³ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21287, United States.

Abstract

•A subset of patients with uterine carcinosarcoma will have ER/PR positive disease.•Hormone receptor expression may serve as a therapeutic target in high-grade endometrial tumors.•Hormonal therapy and SBRT may have benefit in the management of recurrent uterine carcinosarcoma.

Keywords: Aromatase inhibitors; Hormone receptors; Progestin therapy; Uterine carcinosarcoma.

Publication types

Case Reports